Dec 07, 2020 / 01:00PM GMT
Operator
Good morning, and welcome to ImmunoGen's IMGN632 update conference call. Today's conference is being recorded.
At this time, I'd like to turn the call over to Courtney OâKonek, Senior Director of Corporate Communications and Investor Relations. Please go ahead.
Courtney OâKonek - ImmunoGen, Inc. - Senior Director of Corporate Communications & IR
Thanks, Sonia. Good morning, and thank you for joining today's call. On Saturday, updated findings from the Phase I study of IMGN632 in relapsed/refractory BPDCN were presented during an oral session at ASH. Today, we will review those data, discuss the pathway to full approval for 632 in BPDCN as agreed with FDA and provide a progress update on our AML program.
This press release and slides associated with this call can be found under the Investors & Media section of our website at immunogen.com.
On the call today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Dr. Naveen Pemmaraju, Director of the BPDCN program and the
ImmunoGen Inc to Discuss Recent Updates for IMGN632 Conference Call Transcript
Dec 07, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers